These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12590625)

  • 21. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
    Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
    J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
    Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
    Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies.
    Stip E; Zhornitsky S; Potvin S; Tourjman V
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):997-1000. PubMed ID: 20470848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
    Daniel DG; Zimbroff DL; Potkin SG; Reeves KR; Harrigan EP; Lakshminarayanan M
    Neuropsychopharmacology; 1999 May; 20(5):491-505. PubMed ID: 10192829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
    Citrome L; Yang R; Glue P; Karayal ON
    Schizophr Res; 2009 Jun; 111(1-3):39-45. PubMed ID: 19375893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder.
    Citrome L; Reist C; Palmer L; Montejano LB; Lenhart G; Cuffel B; Harnett J; Sanders KN
    Schizophr Res; 2009 Dec; 115(2-3):115-20. PubMed ID: 19864113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using oral ziprasidone effectively: the food effect and dose-response.
    Citrome L
    Adv Ther; 2009 Aug; 26(8):739-48. PubMed ID: 19669631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 39. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
    Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
    Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.